Xavian 10 Tablet contains Rivaroxaban 10 mg, an oral anticoagulant belonging to the class of direct Factor Xa inhibitors. It is indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the coagulation cascade responsible for thrombin generation and clot formation, thereby reducing the risk of clot development. Xavian 10 is administered orally and offers predictable pharmacokinetics and pharmacodynamics, allowing for fixed dosing without the need for routine coagulation monitoring. The recommended dose and duration of therapy depend on the specific indication and patient risk factors. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with active pathological bleeding or significant hypersensitivity to the drug. Common adverse effects include bleeding, anemia, and gastrointestinal disturbances. Patients should be monitored for signs of bleeding and counseled on the importance of adherence and reporting any unusual symptoms. Xavian 10 Tablet should be used under medical supervision, with careful consideration of bleeding risks and potential drug interactions.